Related references
Note: Only part of the references are listed.Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2
Yumei Ye et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
Suppression of rage as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes
Chiara Cuccurullo et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
RhoA-mediated, tumor necrosis factor α-induced activation of NF-κB in rheumatoid synoviocytes -: Inhibitory effect of simvastatin
Hanshi Xu et al.
ARTHRITIS AND RHEUMATISM (2006)
Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome
Sridevi Devaraj et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions
Yumei Ye et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat
Yochai Birnbaum et al.
CIRCULATION (2006)
An ascorbate-dependent artifact that interferes with the interpretation of the biotin switch assay
Bo Huang et al.
FREE RADICAL BIOLOGY AND MEDICINE (2006)
Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment
L Sironi et al.
NEUROBIOLOGY OF DISEASE (2006)
Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2
S Atar et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Survival kinases in ischemic preconditioning and postconditioning
Derek J. Hausenloy et al.
CARDIOVASCULAR RESEARCH (2006)
Signalling networks regulating cyclooxygenase-2
Christos Tsatsanis et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2006)
Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2
SF Kim et al.
SCIENCE (2005)
Role of the protein kinase C-←Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning
YT Xuan et al.
CIRCULATION (2005)
Atorvastatin prevents peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells
A Planavila et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2005)
Compensation of endothelium-dependent responses in coronary circulation of eNOS-deficient mice
S Chlopicki et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size
M Yamakuchi et al.
CIRCULATION RESEARCH (2005)
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment - A potential role for phosphatase and tensin homolog deleted on chromosome ten?
K Mensah et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Atorvastatin and myocardial reperfusion injury - New pleiotropic effect implicating multiple prosurvival signaling
CA Efthymiou et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-κB activation
A Planavila et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2005)
Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury
Y Birnbaum et al.
CARDIOVASCULAR RESEARCH (2005)
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway
DJ Hausenloy et al.
CARDIOVASCULAR RESEARCH (2004)
Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels
S Tavackoli et al.
CORONARY ARTERY DISEASE (2004)
Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway
S Wolfrum et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2004)
Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
MB Harris et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2004)
Optimal windows of statin use for immediate infarct limitation -: 5′-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase
S Sanada et al.
CIRCULATION (2004)
Reduction of myocardial infarct size by fluvastatin
CP Tiefenbacher et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Mechanism of cyclooxygenase-2 upregulation in late preconditioning
YT Xuan et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2003)
Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase
S Wolfrum et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2003)
Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury
R Bolli et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2003)
Reduction of infarct size by short-term pretreatment with atorvastatin
Y Birnbaum et al.
CARDIOVASCULAR DRUGS AND THERAPY (2003)
COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts
K Shinmura et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2002)
Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor
SP Jones et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning
R Bolli et al.
CARDIOVASCULAR RESEARCH (2002)
Differential response to myocardial reperfusion injury in eNOS-deficient mice
BR Sharp et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2002)
Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning
K Shinmura et al.
CIRCULATION RESEARCH (2002)
Nitric oxide as a mediator of delayed pharmacological (A1 receptor triggered) preconditioning;: is eNOS masquerading as iNOS?
RM Bell et al.
CARDIOVASCULAR RESEARCH (2002)
Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion
SP Jones et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice
S Amin-Hanjani et al.
STROKE (2001)
Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits
K Shinmura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.
Y Kureishi et al.
NATURE MEDICINE (2000)
Share Paper
